A randomized, prospective, open-label, multi-center study comparing the efficacy and safety of conversion to SIROLIMUS in stable renal or liver transplant recipients with a cutaneous squamous cell carcinoma.

Trial Profile

A randomized, prospective, open-label, multi-center study comparing the efficacy and safety of conversion to SIROLIMUS in stable renal or liver transplant recipients with a cutaneous squamous cell carcinoma.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 May 2013

At a glance

  • Drugs Sirolimus (Primary) ; Immunosuppressants; Prednisolone
  • Indications Renal transplant rejection; Skin cancer; Squamous cell cancer
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms RESCUE
  • Sponsors Wyeth
  • Most Recent Events

    • 28 Jan 2013 Primary endpoint 'Disease-recurrence-rate' has not been met.
    • 28 Jan 2013 Primary endpoint 'Cancer-specific-survival' has not been met.
    • 07 Sep 2011 Results presented at the 15th Congress of the European Society for Organ Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top